Amdinocillin in combination with beta-lactam antibiotics for treatment of serious gram-negative infections. 1983

C Rotstein, and W E Farrar

Amdinocillin in combination with another beta-lactam antibiotic (ampicillin, cephalothin, cefamandole or cefoxitin) was used to treat 25 patients with pyelonephritis (with or without bacteremia), pneumonia, bacteremia secondary to intravenous devices, and urinary tract infections (with catheter in place) due to gram-negative organisms. The combination resulted in a clinical response in 96 percent of the patients and a bacteriologic response in 100 percent at 72 hours. Few toxic effects were seen. At long-term follow-up, relapse occurred in three of 10 patients with pyelonephritis who were treated with a combination regimen and completed their course of antimicrobial therapy with a beta-lactam antibiotic. Reinfection occurred in one patient who had a urinary tract infection with a catheter in place. In vitro testing showed that the cefamandole-amdinocillin combination most frequently produced synergy against the strains of Escherichia coli isolated. Synergy with the antibiotic combinations was also seen against strains of Klebsiella pneumoniae. It was difficult to correlate the in vitro test results with the in vivo therapeutic effect of these antibiotic combinations.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007710 Klebsiella Infections Infections with bacteria of the genus KLEBSIELLA. Infections, Klebsiella,Infection, Klebsiella,Klebsiella Infection
D007711 Klebsiella pneumoniae Gram-negative, non-motile, capsulated, gas-producing rods found widely in nature and associated with urinary and respiratory infections in humans. Bacillus pneumoniae,Bacterium pneumoniae crouposae,Hyalococcus pneumoniae,Klebsiella pneumoniae aerogenes,Klebsiella rhinoscleromatis
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010397 Penicillanic Acid A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed) Acid, Penicillanic
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004927 Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI. E coli Infections,E. coli Infection,Infections, E coli,Infections, Escherichia coli,E coli Infection,E. coli Infections,Escherichia coli Infection,Infection, E coli,Infection, E. coli,Infection, Escherichia coli
D005260 Female Females

Related Publications

C Rotstein, and W E Farrar
August 1983, The American journal of medicine,
C Rotstein, and W E Farrar
December 2014, Diagnostic microbiology and infectious disease,
C Rotstein, and W E Farrar
December 2020, Current opinion in infectious diseases,
C Rotstein, and W E Farrar
November 1981, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!